Recce Pharmaceuticals Inks Deal With Arrotex for Topical Gel
The agreement grants Arrotex exclusive rights to commercialize RECCE 327 across Australia and New Zealand.
Updated on Oct. 30, 2026 in Healthcare
Live Poll
Do you believe partnerships between biotech and pharmaceutical companies improve access to new medical treatments?
Recce Pharmaceuticals has signed an exclusive licensing agreement with Arrotex Pharmaceuticals for its RECCE 327 topical gel. This partnership covers sales, marketing, and distribution throughout Australia and New Zealand.
Why it matters
The deal provides a streamlined commercial pathway for the product, leveraging Arrotex's established market access to hospitals and pharmacies. It prepares the company for a potential market launch contingent upon successful regulatory approval.
Arrotex maintains a significant footprint in the region, managing approximately 50% of all PBS-approved drugs. Recce Pharmaceuticals retains full control over the manufacturing processes and intellectual property for the compound.
The players
Recce Pharmaceuticals
An Australian-based biotechnology company focused on the development of new anti-infectives.
Arrotex Pharmaceuticals
A major pharmaceutical company that serves as a primary distributor for generic and prescription medications in Australia.
The details
The topical gel is currently under development to treat diabetic foot infections and acute bacterial skin infections. Recce Pharmaceuticals remains focused on its ongoing clinical trials, including a Phase 3 study in Australia and separate research in Indonesia currently under independent expert review.
Timeline
Recce Pharmaceuticals expects to receive data from its Australian Phase 3 study late next year.
Market Landscape
This agreement integrates a new product into the complex distribution network governed by the Australian Pharmaceutical Benefits Scheme (PBS). By partnering with a dominant player, Recce positions its experimental treatment to navigate the highly regulated regional market.
Patients suffering from diabetic foot or acute bacterial skin infections may gain future access to this treatment if it clears regulatory hurdles. The deal ensures that should the product reach the market, it will be supported by an established distribution network.
The takeaway
Commercial partnerships are often essential for biotech firms to translate clinical progress into widespread patient availability. Developing therapies for complex infections requires both scientific success and strategic infrastructure to reach clinical settings effectively.
Further reading
For broader trends in the pharmaceutical sector, visit the Healthcare section.
Live Poll
Do you believe partnerships between biotech and pharmaceutical companies improve access to new medical treatments?
